Digitisation | November 14, 2023
BioPhy launches AI platform to accelerate the drug development market
The company has raised US$4.5 million in funding for its AI operating system
The company has raised US$4.5 million in funding for its AI operating system
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
The collaboration between CARER and Wholeleaf aims to offer an integrated approach to cancer patients, combining services and products to optimize their well-being
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Debut Biotechnology has outstanding enzyme search and design technology and a bio-manufacturing platform (precision fermentation, cell-free synthesis) using those enzymes
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
Subscribe To Our Newsletter & Stay Updated
